SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 7th, 2020 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 4, 2020 by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 7th, 2020 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of December 4, 2020 by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of December 4, 2020 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
ASSET PURCHASE AGREEMENT by and between Syros Pharmaceuticals, Inc., as Buyer and Orsenix, LLC, as Seller Dated as of December 4, 2020Asset Purchase Agreement • December 7th, 2020 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 4, 2020, by and between Syros Pharmaceuticals, Inc., a Delaware corporation (“Buyer”), and Orsenix, LLC, a Georgia limited liability company (“Seller”). Buyer and Seller may be referred to herein, together, as the “Parties” and, individually, as a “Party.”
